RhumbLine Advisers
SBBP

RhumbLine Advisers’s Strongbridge Biopharma plc. SBBP Stock Holding History

RhumbLine Advisers’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,836
Closed -$82K – 3180
2021
Q1 		$82K Buy
29,836
+100
+0.3% +$302 ﹤0.01% 2953
2020
Q4 		$72K Buy
29,736
+4,595
+18% +$11.1K ﹤0.01% 2998
2020
Q3 		$53K Sell
25,141
-8,645
-26% -$29.1K ﹤0.01% 2947
2020
Q2 		$128K Sell
33,786
-5,131
-13% -$15.4K ﹤0.01% 2914
2020
Q1 		$74K Hold
38,917
– – ﹤0.01% 2827
2019
Q4 		$81K Buy
38,917
+606
+2% +$1.16K ﹤0.01% 2892
2019
Q3 		$92K Buy
38,311
+4,811
+14% +$12.9K ﹤0.01% 2899
2019
Q2 		$105K Buy
+33,500
New +$123K ﹤0.01% 2925
2018
Q2 		– Sell
-21,661
Closed -$192K – 2951
2018
Q1 		$192K Buy
21,661
+4,576
+27% +$34.3K ﹤0.01% 2619
2017
Q4 		$124K Sell
17,085
-4,771
-22% -$29.8K ﹤0.01% 2746
2017
Q3 		$151K Buy
21,856
+330
+2% +$2.28K ﹤0.01% 2819
2017
Q2 		$154K Buy
+21,526
New +$99.5K ﹤0.01% 2831

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

RhumbLine Advisers's SBBP Position: Q2 2021 in Review

RhumbLine Advisers sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 29,836 shares — an estimated $82K sold.

RhumbLine Advisers first reported a position in SBBP in Q2 2017 and held it in 12 quarters. The position peaked at $192K in Q1 2018. 59 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

  • RhumbLine Advisers reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 29,836 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $82K.
  • RhumbLine Advisers first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 12 quarters.
  • RhumbLine Advisers's Strongbridge Biopharma plc. position peaked at $192K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.